BRCA1 and ovarian carcinoma: Inhibitors of PARP and histone deacetylase inhibitors have emerged as novel classes of anti-cancer drugs to treat HR-related ovarian cancer associated with BRCA1/2 mutations (Bryant et al., 2005, Farmer et al., 2005, Yano et al., 2018, Yuan et al., 2017).